Figure 5. CFMs suppress expression of transducers of MPM cell growth and survival.

(A–C) CFM treatments result in loss of c-myc in MPM cells. In panel A, cells were either untreated (Control), treated with Adriamycin, Cisplatin, or respective CFMs as in figure 2A, followed by staining of cells using anti-c-myc antibody as detailed in Methods. Presence of c-myc is indicated by intense brown staining in the nuclei of the untreated cells. (B–D) MPM cells were either untreated (denoted as Control in panels C and D, and – in panel B) or treated (denoted as+in panel B) with indicated agents for noted time and dose, and cell lysates were analyzed by western blotting for levels of c-Jun (panel B), c-myc (panels Band C), and cyclin B1 (panels C and D) and actin proteins as in Methods.